Achieve Life Sciences (ACHV) Amortization of Deferred Charges (2024 - 2026)

Achieve Life Sciences (ACHV) has 3 years of Amortization of Deferred Charges data on file, last reported at $12000.0 in Q1 2026.

• Quarterly Amortization of Deferred Charges fell 14.29% year-over-year to $12000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50000.0 (changed N/A YoY) and the FY2025 annual result came in at $52000.0, up 126.09% from the prior year.
• Amortization of Deferred Charges improved to $12000.0 in Q1 2026, from $11000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $14000.0 in Q4 2024 to a low of $11000.0 in Q4 2025.
• A 3-year average of $13000.0 and a median of $13500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2025 — Amortization of Deferred Charges slipped 21.43% — and 2026, when it retreated 14.29%.
• Tracing ACHV's Amortization of Deferred Charges over 3 years: stood at $14000.0 in 2024, then slipped by 21.43% to $11000.0 in 2025, then increased by 9.09% to $12000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $12000.0 (Q1 2026), $11000.0 (Q4 2025), and $13000.0 (Q3 2025), per Business Quant data.